Research and Development Expense	12 Months Ended
Research and Development Expense	Dec. 31, 2015
Research and Development Expense
Research and Development Expense	9. Research and Development Expense Research and development costs include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research, patient costs, drug formulation and tableting, data collection, monitoring and clinical trial insurance. In accordance with FASB ASC Topic 730-10-55, Research and Development, Synergy recorded prepaid research and development costs of approximately $3.1 million and $3.7 million as of December 31, 2015 and December 31, 2014, respectively, for nonrefundable pre-payments for production of drug substance, analytical testing services for its drug candidates and clinical trials. In accordance with this guidance, Synergy expenses deferred research and development costs when drug compound is delivered and/or services are performed.

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.